SCHEMBL2415480

SCHEMBL2415480

CCOc1cnc(S(C)(=O)=O)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
MAPT P10636 3/20 0.44
TP53 P04637 2/20 0.44
MAPK1 P28482 2/20 0.44
HSD17B10 Q99714 2/20 0.44
HTT P42858 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
NPC1 O15118 1/20 0.44
XBP1 P17861 1/20 0.44
TLR9 Q9NR96 1/20 0.44
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
CA7 P43166 1/20 0.41
NQO1 P15559 1/20 0.41
SMN1; SMN2 Q16637 5/20 0.38
POLB P06746 1/20 0.37
LMNA P02545 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5700546 0.79 NQO1 (0.46) ALDH1A1MAPTMAPK1HSD17B10HTT
SCHEMBL4059831 0.78 SMN1; SMN2 (0.47) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL32665217 0.78 LMNA (0.34) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL28944781 0.77 PTGS2 (0.42) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL17394951 0.77 TLR9 (0.35) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL11142475 0.77 CA12 (0.45) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL8113925 0.74 P4HTM (0.54) NPC1CA12CA1CA2CA9
SCHEMBL12143311 0.74 NPC1 (0.42) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL12896114 0.73 GCK (0.38) ALDH1A1MAPTTP53MAPK1HSD17B10
SCHEMBL23036852 0.72 KIF11 (0.40) ALDH1A1MAPTTP53MAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
US-4248618-A Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof ICI AUSTRALIA LIMITED (AU) 1981-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG ALDH1A1 175/4885MAPT 3435/4885TP53 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.